Format

Send to

Choose Destination
Hepatology. 2019 Dec 9. doi: 10.1002/hep.31060. [Epub ahead of print]

Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

Author information

1
Investigator, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health Bethesda, MD.
2
Assistant Professor of Medicine, Weill Cornell Medicine, New York, NY.
3
Chief of Hepatology, Veterans Affairs Long Beach Healthcare System Long Beach, CA.
4
Chief Division of Infectious Diseases, Denver Health Denver, CO.
5
Assistant Professor of Medicine, University of Chicago Medical Center Chicago, IL.
6
Assistant Clinical Professor of Medicine, University of California Los Angeles, Santa Monica, CA.
7
Administrative Manager, Building Equity and Alignment for Impact Calabasas, CA.
8
Assistant Professor of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
9
Assistant Professor of Medicine and Research Director of Gastroenterology, Medicine Toronto Western Hospital Liver Center, Toronto, ON, Canada.
10
Wayne State University School of Medicine, Director of Hepatology, Henry Ford Health System Detroit, MI.
11
Chief of Translational Hepatology Unit, Liver Diseases Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
12
Associate Division Head, Pediatric Infectious Diseases Ann & Robert H. Lurie Children's Hospital of Chicago Professor of Pediatrics, Feinberg Northwestern School of Medicine, Chicago, IL.
13
Clinical Director, Hepatology Director, Center for Childhood Liver Disease/Professor of Pediatrics Harvard Medical School, Boston Children's Hospital Boston, MA.
14
Assistant Professor and Associate Director of the Center for Translational Pharmacokinetics and Pharmacogenomics, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO.
15
Assistant Professor of Medicine, Boston University School of Medicine, Boston, MA.
16
Associate Professor of Medicine and Epidemiology, University of Pennsylvania Perelman School of Medicine, Division of Infectious Diseases and Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA.
17
Chief of Hepatology Research, University of California San Francisco, San Francisco, CA.
18
Director of Hepatology, Hospital of the University of Pennsylvania, Philadelphia, PA.
19
Hepatitis C Wellness Manager, San Francisco AIDS Foundation, San Francisco, CA.
20
Associate Professor of Medicine Hepatitis and Liver Clinic, University of Washington Seattle, WA.
21
Executive Director, Coalition on Positive Health Empowerment New York, NY.
22
U.S. Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA.
23
Professor of Medicine, Chief of the Division of Gastrointestinal and Liver Diseases, University of Southern California Keck School of Medicine, Los Angeles, CA.
24
Jonathan Lax Treatment Center, Philadelphia FIGHT, Viral Hepatitis Program, Philadelphia, PA.
25
Columbia University Irving Medical Center New York, NY.
26
Professor of Medicine and Chief of the Division of Clinical Decision Making, Tufts University School of Medicine, Boston, MA.
27
nstructor in Medicine, Department of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
28
Professor of Medicine, Emory University School of Medicine, Atlanta, GA.

Abstract

The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) initiated the hepatitis C guidance project (hereafter HCV guidance) in 2013. The AASLD-IDSA HCV guidance website (www.HCVGuidelines.org) disseminates up-to-date, peer-reviewed, unbiased, evidence-based recommendations to aid clinicians making decisions regarding the testing, management, and treatment of hepatitis C virus (HCV) infection. Utilizing a web-based system enables timely and nimble distribution of the HCV guidance, which is periodically updated in near real time as necessitated by emerging research data, recommendations from public health agencies, the availability of new therapeutic agents, or other significant developments affecting the rapidly evolving hepatitis C arena.

KEYWORDS:

HCV guidance; HCV screening; chronic HCV treatment; direct-acting antiviral treatment

PMID:
31816111
DOI:
10.1002/hep.31060

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center